Foundayo noninferior to insulin glargine for CV outcomes
Healio reports on ACHIEVE-4, a Lilly-funded trial in which 2,749 patients with type 2 diabetes, overweight or obesity and established cardiovascular or kidney disease received oral orforglipron (Foundayo) or insulin glargine. At a median 2 years, major cardiovascular events occurred in 4.2% versus 5%, meeting noninferiority. The trial was not powered for superiority. Hypoglycemia was less common with orforglipron, while GI adverse events were more common.
Why it matters: Relevant to Maryland adults with type 2 diabetes, excess weight and cardiovascular or kidney disease, and to the endocrinology and cardiology clinicians who care for them.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to healio.com. October 3, 2026.